Steroid levels in crinoid echinoderms are altered by exposure to model endocrine disruptors.
Sexual steroids (testosterone and estradiol) were measured in the whole body of wild specimens of the crinoid Antedon mediterranea collected from the Tyrrhenian Sea (Italy). Testosterone levels (274-1,488 pg/g wet weight (w.w.)) were higher than those of estradiol (60-442 pg/g w.w.) and no significant differences between males and females were observed. No clear seasonal trend was either detected - individuals from February, June and October 2004 analyzed - apart from a peak of estradiol in males in autumn. Nonetheless, dramatic changes on tissue steroid levels were observed when individuals were exposed to model androgenic and anti-androgenic compounds for 2 and 4 weeks. The selected compounds were 17 alpha-methyltestosterone (17 alpha-MT), triphenyltin (TPT), fenarimol (FEN), cyproterone acetate (CPA), and p,p'-DDE. Endogenous testosterone levels were significantly increased after exposure to 17 alpha-MT, TPT and FEN, while different responses were observed for estradiol; 17 alpha-MT and FEN increased endogenous estradiol (up to seven-fold), and TPT lead to a significant decrease. Concerning the anti-androgenic compounds, CPA significantly reduced testosterone in a dose-dependent manner without altering estradiol levels, whereas specimens exposed to p,p'-DDE at a low dose (24 ng/L) for 4 weeks showed a four-fold increase in T levels. Overall, the data show the ability of the selected compounds to alter endogenous steroid concentrations in A. mediterranea, and suggest the existence in this echinoderm species of vertebrate-like mechanisms that can be affected by exposure to androgenic and anti-androgenic chemicals.
Lavado
Ramón
R
Environmental Chemistry Department IIQAB-CSIC, C/Jordi Girona, 18, 08034 Barcelona, Spain.
Barbaglio
Alice
A
Carnevali
M Daniela Candia
MD
Porte
Cinta
C
D000726:Androgen Antagonists / Q000494:pharmacology*; D000818:Animals; D017373:Cyproterone Acetate / Q000494:pharmacology; D003633:Dichlorodiphenyl Dichloroethylene / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004447:Echinodermata / Q000378:metabolism*; D052244:Endocrine Disruptors / Q000494:pharmacology*; D004781:Environmental Exposure / Q000009:adverse effects*; D004958:Estradiol / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D008297:Male; D008777:Methyltestosterone / Q000494:pharmacology; D009947:Organotin Compounds / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D013256:Steroids / Q000032:analysis* / Q000378:metabolism; D013739:Testosterone / Q000032:analysis / Q000378:metabolism; D013997:Time Factors
D000726:Androgen Antagonists; D052244:Endocrine Disruptors; D009947:Organotin Compounds; D011743:Pyrimidines; D013256:Steroids; D013739:Testosterone; D017373:Cyproterone Acetate; D003633:Dichlorodiphenyl Dichloroethylene; D004958:Estradiol; C030665:triphenyltin; C033789:fenarimol; D008777:Methyltestosterone